Anti-obesity drugs like the glucagon-like peptide-1 (GLP-1) agonists liraglutide and semaglutide improve hepatic steatosis, possibly though an mTOR- and AMPK-mediated pathway [17,18]. This evidence concerns the gene GLP1R and Hepatic steatosis.